111 Inc stock (KYG6769N1008): Analyst upgrade to Hold amid recent price volatility

111 Inc (YI) received an analyst upgrade to Hold/Accumulate on May 13, 2026, as the stock traded around $7.32 following a reverse split and modest daily moves.

111 Inc, a leading online retail platform in China, saw its stock upgraded to Hold/Accumulate by analysts at StockInvest.us on May 13, 2026. The rating reflects ongoing volatility, with shares closing at $7.32 on July 25, 2025, after a -0.81% decline, according to StockInvest.us as of Jul 25, 2025. Earlier, the company executed a 1-for-10 reverse stock split, impacting share structure as noted by Robinhood on their corporate actions tracker.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: 111, Inc.
• Sector/industry: E-commerce/Healthcare Retail
• Headquarters/country: China
• Core markets: China
• Key revenue drivers: Online pharmacy and health products
• Home exchange/listing venue: Nasdaq (YI)
• Trading currency: USD

111 Inc: core business model

111 Inc operates as an online retail platform focused on pharmaceutical and consumer health products in China. The company connects consumers, pharmacies, and suppliers through its digital marketplace, emphasizing authenticity and convenience in healthcare shopping. Listed on Nasdaq under ticker YI, it serves as a key player for US investors seeking exposure to China's e-commerce health sector.

Main revenue and product drivers for 111 Inc

Revenue primarily stems from online sales of prescription drugs, over-the-counter medications, and wellness products. The platform's pharmacy network and supply chain logistics drive growth, with a focus on tier-1 and tier-2 cities in China. This model benefits from rising health awareness and digital adoption among Chinese consumers.

Industry trends and competitive position

China's online pharmacy market is expanding rapidly, driven by aging populations and policy support for e-health. 111 Inc competes with players like JD Health and Alibaba Health, differentiating through its B2C and B2B hybrid model. For US investors, the stock offers a way to tap into this high-growth sector amid US-China trade dynamics.

Why 111 Inc matters for US investors

As a Nasdaq-listed ADR, 111 Inc provides US retail investors direct access to China's healthcare e-commerce boom without navigating local exchanges. Its exposure to consumer spending trends in the world's second-largest economy adds diversification potential to portfolios heavy in domestic tech or retail names.

Conclusion

The recent analyst upgrade to Hold signals stabilizing sentiment for 111 Inc amid post-split trading and price fluctuations around $7.32. Investors monitor corporate actions and market trends in China for further developments. The company's position in digital health retail remains a focal point for growth-oriented exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.